NCT05258266View on ClinicalTrials.gov

A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

April 30, 2024

Conditions
Advanced Solid Tumor
Interventions
DRUG

ZX-101A

Q.D., oral dosing

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Nanjing Zenshine Pharmaceuticals

INDUSTRY

NCT05258266 - A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter